CSB

Stanford School of Medicine

Chemical & Systems Biology

 
 

Additive protection of the ischemic heart ex vivo by combined treatment with delta-protein kinase C inhibitor and epsilon-protein kinase C activator.

Posted by CSB Department on August 19, 2003

Inagaki K, Hahn HS, Dorn GW, Mochly-Rosen D. (2003) Circulation 108(7):869-75 [PubMed]